Monday morning brought a double shot of positive phase III data in second-line renal cell carcinoma (RCC) from Exelixis Inc.'s multityrosine kinase inhibitor cabozantinib and Bristol-Myers Squibb Co.'s nivolumab, even as the prospect of combination therapy heralds a changing landscape in RCC treatment. Read More
Cellceutix Inc.'s chief medical officer Daniel Jorgenson told BioWorld Today that "momentum was growing" with brilacidin against acute bacterial skin and skin structure infection (ABSSSI) at Polymedix Inc. before the firm went bankrupt in 2013 and sold off its assets. Read More
SHANGHAI – Phagelux Inc., a Shanghai-based company developing bacteriophages for both human and animal use, has acquired Omnilytics Inc. as part of a mission to leverage phage technology in the battle against antibiotic overuse. Read More
Would-be biosimilar makers are finding that shaping a new market in the U.S. is easier said than done, given the regulatory tangle that seems to ensnare the process at every step of the way. Read More
Fibrocell Science Inc. and Intrexon Corp. took their partnership to the next level with the submission of an investigational new drug (IND) application with the FDA for FCX-007, a gene-therapy drug candidate to treat the orphan condition recessive dystrophic epidermolysis bullosa, or RDEB. Read More
Vtv Therapeutics Inc., of High Point, N.C., set terms for its IPO of approximately 7.8 million common shares, which are expected to price between $15 and $17, and granted underwriters the option to purchase up to about 1.17 million additional common shares to cover overallotments. Read More
Biorestorative Therapeutics Inc., of Melville, N.Y., said it began to evaluate encapsulation technology for potential use as a cell delivery system for its metabolic program. Read More
Alnylam Pharmaceuticals Inc., of Cambridge, Mass., initiated its phase III open-label extension study, APOLLO-OLE, with patisiran, its RNAi candidate targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis in patients with familial amyloidotic polyneuropathy, or FAP. Read More
